Aratana Therapeutics Inc. (NASDAQ:PETX)’s share price traded down 4.9% during trading on Wednesday . The stock traded as low as $8.62 and last traded at $8.78, with a volume of 429,108 shares trading hands. The stock had previously closed at $9.23.

Several equities analysts recently commented on the company. Jefferies Group assumed coverage on Aratana Therapeutics in a report on Friday, August 19th. They issued a “buy” rating and a $13.00 target price on the stock. William Blair reissued an “outperform” rating on shares of Aratana Therapeutics in a report on Wednesday, August 17th. Barclays PLC dropped their target price on Aratana Therapeutics from $15.00 to $11.00 and set an “overweight” rating on the stock in a report on Thursday, August 11th. Credit Suisse Group AG reissued a “buy” rating and issued a $11.00 target price on shares of Aratana Therapeutics in a report on Wednesday, August 10th. Finally, Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, July 28th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Aratana Therapeutics has a consensus rating of “Buy” and an average price target of $11.28.

The stock’s market cap is $314.66 million. The stock has a 50-day moving average of $8.17 and a 200 day moving average of $6.37.

Aratana Therapeutics (NASDAQ:PETX) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.24 by $0.37. The business had revenue of $38.05 million for the quarter, compared to analyst estimates of $15.14 million. During the same quarter in the previous year, the firm posted ($0.23) EPS. On average, equities research analysts forecast that Aratana Therapeutics Inc. will post ($0.73) EPS for the current year.

In other Aratana Therapeutics news, insider Ernst Heinen sold 15,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $6.72, for a total value of $100,800.00. Following the transaction, the insider now owns 125,494 shares in the company, valued at approximately $843,319.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Peter Steven St sold 50,000 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $9.25, for a total transaction of $462,500.00. Following the completion of the transaction, the insider now owns 642,793 shares in the company, valued at approximately $5,945,835.25. The disclosure for this sale can be found here.

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.